Track Artivion Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Artivion Inc. Common Stock AORT Open Artivion Inc. Common Stock in new tab

34.21 USD
P/E
168.05
EPS
0.21
P/B
3.77
ROE
2.70
Beta
1.64
Target Price
51.43 USD
Artivion Inc. Common Stock logo

Artivion Inc. Common Stock

🧾 Earnings Recap – Q3 2025

Artivion delivered robust Q3 2025 results with constant currency revenue growth of 16% and adjusted EBITDA growth of 39%, driven by strong performance from stent grafts and On-X valves.

  • Stent graft revenues surged 31% year-over-year, supported by the early adoption of AMDS, positioning it as a key growth driver.
  • On-X valves achieved a 23% revenue increase, benefiting from market share gains and the unique clinical advantages of the product.
  • The recent CMS reimbursement update for complex aortic procedures is expected to enhance the economic proposition of AMDS, further driving adoption.
  • Investment in expanded operational capacity in Austin, Texas indicates proactive measures to support anticipated growth in the On-X business.
  • Artivion maintains a strong pipeline of clinical evidence and promising early commercial traction across its product portfolio.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 4, 2026
P/E168.05
EPS0.21
Book Value9.37
Price to Book3.77
Debt/Equity57.67
% Insiders4.159%
Growth
Revenue Growth0.19%
Estimates
Forward P/E30.53
Forward EPS1.16
Target Mean Price51.43

DCF Valuation

Tweak assumptions to recompute fair value for Artivion Inc. Common Stock (AORT)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Artivion Inc. Common Stock Logo Artivion Inc. Common Stock Analysis (AORT)

United States Health Care Official Website Stock

Is Artivion Inc. Common Stock a good investment? Artivion Inc. Common Stock (AORT) is currently trading at 34.21 USD. Market analysts have a consensus price target of 51.43 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 168.05. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Artivion Inc. Common Stock is expected to release its next earnings report on May 4, 2026. The market consensus estimate for Forward EPS is 1.16.

Investor FAQ

Does Artivion Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Artivion Inc. Common Stock?

Artivion Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 4, 2026. The company currently has a trailing EPS of 0.21.

Company Profile

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Exchange Ticker
ASE (United States) AORT
NYQ (United States) CRY
Historical Dividends
Year Total Dividends
2015 0.12 USD
2014 0.12 USD
2013 0.11 USD
2012 0.05 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Dec. 28, 2000 1.500000
July 1, 1996 2.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion